Wednesday, July 22 brought a burst of AI-adjacent and fintech upgrades and initiations, plus a fresh biotech Buy. Q2 earnings continue at pace across tech, financials, and industrials this week. The macro backdrop remains Chair Kevin Warsh's June 17 FOMC hold at 3.50%–3.75% and a CME FedWatch reading pricing roughly an 80% probability of zero rate cuts through year-end 2026. Five names drew fresh Buy signals for Thursday, July 23.
DigitalOcean Holdings (DOCN) — Stifel buys the pullback in the cloud provider
DigitalOcean is a cloud infrastructure provider focused on developers, startups, and small and mid-sized businesses, offering compute, managed databases, Kubernetes, and an expanding AI/ML product suite through Paperspace and Gradient. On July 22, Stifel analyst Brad Reback upgraded the stock from Hold to Buy and lifted his target from $135 to $160, citing incremental positive data points and a roughly 30% pullback from recent highs. Baird's Rob Oliver separately initiated coverage at Outperform with a $165 target the same day.
Shares traded at $140.26 midday July 22, up 2.79%, with a market cap of $14.6 billion and a trailing P/E of 77.92. Trailing EPS was $1.80 and the company pays no dividend. The 52-week range is $25.56 to $187.50. The consensus rating is Strong Buy, with 9 of 11 analysts bullish (81.8%), an average target of $154.18, a median of $160, a high of $200, and a low of $105.
Risks: DigitalOcean's SMB customer base is more sensitive to economic slowdowns than enterprise-anchored cloud peers; hyperscalers continue to bundle developer-friendly services; AI product revenue is still small relative to the traditional cloud base; and Piper Sandler's James Fish holds Neutral at $155, roughly at the current share price.
CoreWeave (CRWV) — Truist and Baird turn constructive on the AI cloud pure play
CoreWeave is a specialty AI-cloud provider that operates high-density GPU clusters primarily for training and inference workloads, with capacity concentrated on NVIDIA H100 and H200 systems and rapidly expanding U.S. and European data-center footprint. On July 22, Truist Securities analyst Arvind Ramnani upgraded the stock from Hold to Buy at $126 target, citing broadening medium-term demand from enterprise adoption of open-weight models. Baird's Rob Oliver separately initiated coverage at Outperform with a $100 target the same day, calling out CoreWeave's ability to deliver capacity ahead of peers.
Shares traded at $82.66 midday July 22, up 3.87%, with a market cap of $45.1 billion and a company still unprofitable, so a trailing P/E is not meaningful. Trailing EPS was negative $2.02 and the company pays no dividend. The 52-week range is $63.80 to $153.20, with shares roughly 46% below the cycle high. The consensus rating is Buy, with 8 of 13 analysts bullish (61.5%), an average target of $134.46, a median of $130, a high of $250, and a low of $67.
Risks: GPU capacity buildout requires heavy capex against uncertain long-term utilization; Microsoft customer concentration remains meaningful; hyperscaler competition on price and product breadth is intensifying; and Bernstein's Madison Rezaei holds Underperform at $67, well below the current share price.
Genmab (GMAB) — TD Cowen upgrades the Danish biotech to Buy
Genmab is a Danish biotechnology company with a differentiated antibody platform, best known for royalties on Johnson & Johnson's DARZALEX and TEPKINLY as well as owned programs in bispecifics and antibody-drug conjugates targeting hematologic and solid-tumor cancers. On July 22, TD Cowen analyst Yaron Werber upgraded the stock from Hold to Buy and lifted his target from $32 to $43, a $11 hike. The call joins Truist Securities' Asthika Goonewardene at Buy $48, the Street high, and HC Wainwright's Raghuram Selvaraju at Buy $40.
Shares traded at $29.07 midday July 22, up 2.50%, with a market cap of $17.8 billion and a trailing P/E of 20.92. Trailing EPS was $1.39 and the company pays no meaningful dividend. The 52-week range is $21 to $35.43. The consensus rating is Strong Buy, with all 4 covering analysts bullish (100%), an average target of $42.75, a median of $41.50, a high of $48, and a low of $40.
Risks: DARZALEX faces increasing competition from next-generation multiple-myeloma therapies including BCMA-targeted CAR-Ts and bispecifics; EPKINLY's launch in follicular lymphoma requires meaningful commercial investment; foreign-exchange volatility on Danish krone earnings translation adds noise; and Guggenheim's Michael Schmidt sits near the low end of the range at Buy $40.
Affirm Holdings (AFRM) — Bernstein initiates the buy-now-pay-later leader at Outperform
Affirm Holdings is the largest U.S. buy-now-pay-later platform, offering point-of-sale installment loans at merchant partners including Amazon, Shopify, and Walmart, with a differentiated approach that has expanded from 0% APR promotional financing to a broader consumer credit portfolio. On July 22, Bernstein initiated coverage at Outperform, citing an impressive growth trajectory and calling the fintech-sector malaise since April an opportunity to get involved despite recent outperformance. Cantor Fitzgerald's Ramsey El-Assal separately maintained Overweight and lifted his target from $80 to $88 the same day.
Shares traded at $74.40 midday July 22, down 0.43%, with a market cap of $24.9 billion and a trailing P/E of 67.64. Trailing EPS was $1.10 and the company pays no dividend. The 52-week range is $42.09 to $100. The consensus rating is Buy, with 13 of 18 analysts bullish (72.2%), an average target of $91.72, a median of $89, a high of $117, and a low of $75.
Risks: Consumer credit performance is sensitive to labor-market softening and can pressure loss provisions; regulatory scrutiny of BNPL disclosures continues at the CFPB; funding costs on the securitization side rise with credit spreads; and Baird's David Koning holds Neutral at $82, cautious on unit economics after the recent rally.
Generac Holdings (GNRC) — Cantor Fitzgerald initiates the backup-power leader at Overweight
Generac Holdings is the leading U.S. producer of home standby generators, commercial and industrial backup power systems, and a growing clean-energy portfolio including PWRcell batteries and grid-services offerings under the Ecobee brand. On July 22, Cantor Fitzgerald initiated coverage at Overweight with a $325 price target, citing sustained bullish views on residential backup power demand and the emerging battery-storage attach opportunity. Recent Street calls include Citigroup's Vikram Bagri at Neutral $300 and UBS's Jon Windham at Buy $335.
Shares traded at $215.10 midday July 22, down 0.24%, with a market cap of $12.7 billion and a trailing P/E of 31.22. Trailing EPS was $6.89 and the company pays no dividend. The 52-week range is $134.80 to $296.44. The consensus rating is Strong Buy, with 12 of 14 analysts bullish (85.7%), an average target of $277.50, a median of $285, a high of $335, and a low of $199.
Risks: Home standby generator demand can be lumpy quarter to quarter given its dependence on major storm activity; competition from Kohler, Briggs & Stratton, and Cummins remains stiff; the clean-energy segment has yet to demonstrate durable profitability; and Barclays' Christine Cho holds Equal-Weight at $285, at the lower end of the bullish range.
Found this helpful? Share it with others.